Sylvie Mader, IRIC, Montréal, Qc, Canada
"Estrogen signalling and its inhibition for breast cancer treatment"
After training in France at Ecole Normale Supérieure de Paris, Université Paris VI and Institut Pasteur, Sylvie Mader joined the team of Professor Pierre Chambon in Strasbourg for a Ph.D. in Biochemistry at the Laboratoire de Génétique Moléculaire des Eucaryotes, during which she characterized the mechanisms of target gene regulation by nuclear receptors. She then trained as a postdoctoral fellow with Professor Nahum Sonenberg at the Biochemistry department at McGill University, where she uncovered a mechanism of translational control involving formation of competitive complexes with the translation intiation factor eIF4E. Sylvie Mader put together her research team at Université de Montréal in 1995, with a focus on the therapeutic modulation of molecular signaling pathways involved in breast cancer. Since joining IRIC in 2005, Sylvie Mader and her team use cutting-edge technologies such as functional genomics, proteomics, bioinformatics and biophysics to identify novel therapeutic targets and design new drugs for breast cancer treatment. In particular, her team is studying nuclear receptor signaling pathways, which are attractive targets for drug development. She is also analyzing the mechanisms of mammary cell differentiation and tumorigenesis in cultured cells and animal models.